Anthony D'Urzo
- ACCORD COPD I: Safety and tolerability of twice daily aclidinium bromide in COPD patientsBy Anthony D'Urzo, Barry Make, Edward Kerwin, Ludmyla Rekeda, Esther Garcia Gil, Cynthia Caracta and Brian MaurerAnthony D'Urzo1Department of Family and Community Medicine, University of Toronto, Toronto, CanadaBarry Make2Department of Medicine, National Jewish Medical & Research Center, Denver, United StatesEdward Kerwin3Medical, Allergy & Asthma Center of Southern Oregon, PC, Medford, United StatesLudmyla Rekeda4Biostatistics, Forest Research Institute, Jersey City, United StatesEsther Garcia Gil5R&D Centre, Almirall SA, Barcelona, SpainCynthia Caracta6Clinical Development, Forest Research Institute, Jersey City, United StatesBrian Maurer6Clinical Development, Forest Research Institute, Jersey City, United States
- ACCORD COPD I: Twice-daily aclidinium bromide improves quality of life and dyspnea in COPD patientsBy Arthur Gelb, James Donohue, Anthony D'Urzo, Ludmyla Rekeda, Esther Garcia Gil and Jordan LateinerArthur Gelb1Respiratory Division, Southern California Clinical Trials, Lakewood, United StatesJames Donohue2Department of Medicine, University of North Carolina, School of Medicine, Chapel Hill, United StatesAnthony D'Urzo3Department of Family and Community Medicine, University of Toronto, Toronto, CanadaLudmyla Rekeda4Biostatistics, Forest Research Institute, Jersey City, United StatesEsther Garcia Gil5R&D Centre, Almirall SA, Barcelona, SpainJordan Lateiner6Clinical Development, Forest Research Institute, Jersey City, United States
- Dual bronchodilation with QVA149 reduces patient-reported dyspnoea in COPD: the BLAZE studyBy Donald A. Mahler, Marc Decramer, Anthony D'Urzo, Heinrich Worth, Tracy White, Vijay K.T. Alagappan, Hungta Chen, Nicola Gallagher, Károly Kulich and Donald BanerjiDonald A. Mahler1Section of Pulmonary and Critical Care Medicine, Geisel School of Medicine at Dartmouth, Hanover, NH, USAMarc Decramer2Division of Respiratory Medicine, University Hospital, Katholieke Universiteit, Leuven, BelgiumAnthony D'Urzo3Dept of Family and Community Medicine, Faculty of Medicine, University of Toronto, Toronto, ON, CanadaHeinrich Worth4Dept of Pneumology and Cardiology, Hospital Fürth, University Erlangen-Nürnberg, Fürth, GermanyTracy White5Novartis Pharmaceuticals Corporation, East Hanover, NJ, USAVijay K.T. Alagappan5Novartis Pharmaceuticals Corporation, East Hanover, NJ, USAHungta Chen5Novartis Pharmaceuticals Corporation, East Hanover, NJ, USANicola Gallagher6Novartis Horsham Research Centre, Horsham, UKKároly Kulich7Novartis Pharma AG, Basel, SwitzerlandDonald Banerji5Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
- Twice-daily aclidinium bromide in COPD patients: A pooled analysis of lung function in the ACCORD-COPD I and ATTAIN trialsBy Edward Kerwin, Paul Jones, Anthony D'Urzo, Ludmyla Rekeda, Esther Garcia Gil and Cynthia CaractaEdward Kerwin1Clinical Research Institute, Medford, United StatesPaul Jones2Division of Clinical Sciences, St. George's University, London, United KingdomAnthony D'Urzo3Family & Community Medicine, University of Toronto, CanadaLudmyla Rekeda4Biostatistics, Forest Research Institute, Jersey City, United StatesEsther Garcia Gil5R&D Centre, Almirall, S.A., Barcelona, United StatesCynthia Caracta6Clinical Development, Forest Research Institute, Jersey City, United States
- Influence of different spirometry interpretation algorithms (SIA) on decision making among primary care physiciansBy Anthony D'Urzo, Pieter Jugovic and Reuven JhiradAnthony D'Urzo1Department of Family and Community Medicine (DFCM), University of Toronto, ON, CanadaPieter Jugovic2Department of Family and Community Medicine (DFCM), University of Toronto, ON, CanadaReuven Jhirad3Department of Family and Community Medicine (DFCM), University of Toronto, Burlington, ON, Canada
- Effects of twice-daily aclidinium bromide in COPD patients: A long-term extension of ACCORD-COPD IBy Anthony D'Urzo, Edward Kerwin, James Donohue, Stephen Rennard, Arthur Gelb, Hassan Lakkis, Esther Garcia Gil and Cynthia CaractaAnthony D'Urzo1Department of Family & Community Medicine, University of Toronto, CanadaEdward Kerwin2Clinical Research Institute, Medford, United StatesJames Donohue3Department of Medicine, University of North Carolina, Chapel Hill, United StatesStephen Rennard4Department of Internal Medicine, University of Nebraska Medical Center, Omaha, United StatesArthur Gelb5Southern California Clinical Trials, Lakewood, United StatesHassan Lakkis6Biostatistics, Forest Research Institute, Jersey City, United StatesEsther Garcia Gil7R&D Centre, Almirall, S.A., Barcelona, SpainCynthia Caracta8Clinical Development, Forest Research Institute, Jersey City, United States
- Once-daily QVA149 demonstrates superior improvements in patient-reported dyspnea compared to tiotropium in patients with moderate-to-severe COPD: The BLAZE studyBy Donald A. Mahler, Marc Decramer, Anthony D'Urzo, Heinrich Worth, Tracy White, Vijay Alagappan, Hungta Chen, Karoly Kulich, Nicola Gallagher and Donald BanerjiDonald A. Mahler1Department of Medicine, Geisel School of Medicine, Dartmouth, Hanover, United StatesMarc Decramer2Department of Respiratory Medicine, University Hospital, Katholieke Universiteit, Leuven, BelgiumAnthony D'Urzo3Department of Family and Community Medicine, University of Toronto, Toronto, CanadaHeinrich Worth4Departments of Pulmonology and Cardiology, Hospital Fürth, University Erlangen-Nürnberg, Fürth, GermanyTracy White5Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesVijay Alagappan5Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesHungta Chen5Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesKaroly Kulich6Primary Care, Novartis Pharma AG, Basel, SwitzerlandNicola Gallagher7Primary Care, Novartis Horsham Research Centre, Horsham, United KingdomDonald Banerji5Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States
- Once-daily QVA149 provides clinically meaningful improvements in lung function and clinical outcomesBy Claus Vogelmeier, Ronald Dahl, Anthony D'Urzo, Hungta Chen, Yulia Green and Donald BanerjiClaus Vogelmeier1Department of Respiratory Medicine, Universitätsklinikum Gießen Und Marburg, Marburg, GermanyRonald Dahl2Department of Respiratory Diseases, Aarhus University Hospital, Aarhus, DenmarkAnthony D'Urzo3Department of Family and Community Medicine (DFCM), University of Toronto, Ontario, CanadaHungta Chen4Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesYulia Green5Primary Care, Novartis Horsham Research Centre, Horsham, United KingdomDonald Banerji4Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States
- Dual bronchodilation with QVA149 reduces patient-reported dyspnoea in COPD: BLAZE studyBy Donald A Mahler, Marc Decramer, Anthony D'Urzo, Heinrich Worth, Tracy White, Vijay K. T. Alagappan, Hungta Chen, Nicola Gallagher, Károly Kulich and Donald BanerjiArticle | Published in 2013 in European Respiratory JournalDonald A Mahler*Section of Pulmonary & Critical Care Medicine; Geisel School of Medicine at Dartmouth; Hanover, NH, USAMarc Decramer#Division of Respiratory Medicine, University Hospital, Katholieke Universiteit, Leuven, BelgiumAnthony D'Urzo¶Dept of Family and Community Medicine, Faculty of Medicine, University of Toronto, Toronto, ON, CanadaHeinrich Worth+Depts of Pneumology and Cardiology, Hospital Fürth, University Erlangen-Nürnberg, Fürth, GermanyTracy White§Novartis Pharmaceuticals Corporation, East Hanover, NJ, USAVijay K. T. Alagappan§Novartis Pharmaceuticals Corporation, East Hanover, NJ, USAHungta Chen§Novartis Pharmaceuticals Corporation, East Hanover, NJ, USANicola GallagherfNovartis Horsham Research Centre, Horsham, UKKároly Kulich**Novartis Pharma AG, Basel, SwitzerlandDonald Banerji§Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
- Lung function improvements with twice-daily aclidinium/formoterol fixed-dose combination in two 24-week studies in patients with COPDBy Dave Singh, Anthony D'Urzo, Paul Jones, Cristina Serra, Victor Mergel, Cynthia Caracta and Anne LeselbaumDave Singh1Medicines Evaluation Unit Ltd, University of Manchester, Manchester, United KingdomAnthony D'Urzo2Department of Medicine, University of Toronto, Toronto, CanadaPaul Jones3Division of Clinical Science, St George's, University of London, London, United KingdomCristina Serra4R&D Centre, Almirall S.A., Barcelona, SpainVictor Mergel5Forest Research Institute, Jersey City,Cynthia Caracta5Forest Research Institute, Jersey City,Anne Leselbaum4R&D Centre, Almirall S.A., Barcelona, Spain
- Cardiovascular (CV) safety of aclidinium bromide/formoterol fumarate fixed dose combination (FDC) in COPD: Pooled analyses of three Phase III studiesBy James F. Donohue, Eric D. Bateman, Anthony D'Urzo, Pomy Shrestha, Anne Leselbaum and Alejhandra LeiJames F. Donohue1Department of Internal Medicine, University of North Carolina, Chapel Hill, NC,Eric D. Bateman2Division of Pulmonology, University of Cape Town Lung Institute, Cape Town, South AfricaAnthony D'Urzo3Department of Family and Community Medicine, Faculty of Medicine, University of Toronto, Toronto, CanadaPomy Shrestha4Forest Research Institute, Forest Laboratories Inc, NJ,Anne Leselbaum5Almirall R&D Centre, Almirall S.A., Barcelona, SpainAlejhandra Lei5Almirall R&D Centre, Almirall S.A., Barcelona, Spain
- QVA149 showed significant improvements in lung function and health status and was well tolerated versus glycopyrronium and tiotropium in patients with severe COPD: The SPARK studyBy Jadwiga A. Wedzicha, Anthony D'Urzo, Karen Mezzi, Hungta Chen, Donald Banerji and Robert FogelJadwiga A. Wedzicha1Centre for Respiratory Medicine, University College London, Royal Free Hospital, London, United KingdomAnthony D'Urzo2Department of Family and Community Medicine, Faculty of Medicine, University of Toronto, Toronto, ON, CanadaKaren Mezzi3Primary Care, Novartis Pharma AG, Basel, SwitzerlandHungta Chen4Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ,Donald Banerji4Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ,Robert Fogel4Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ,
- QVA149 improves dyspnoea and lung function versus tiotropium in symptomatic patients using LABA/ICS preceding study enrolment: The BLAZE studyBy Anthony D'Urzo, Donald A. Mahler, Caglar Karakurum, Hungta Chen, Robert Fogel and Donald BanerjiAnthony D'Urzo1Department of Family and Community Medicine, University of Toronto, Toronto, ON, CanadaDonald A. Mahler2Section of Pulmonary and Critical Care Medicine, Geisel School of Medicine at Dartmouth, Hanover, NH,Caglar Karakurum3Primary Care, Novartis Pharma AG, Basel, SwitzerlandHungta Chen4Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ,Robert Fogel4Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ,Donald Banerji4Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ,
- Effect of aclidinium/formoterol fixed-dose combinations on respiratory symptoms in COPD patientsBy Paul Jones, Anthony D'Urzo, Stephen Rennard, Eduard Molins, Victor Mergel, Cynthia Caracta and Anne LeselbaumPaul Jones1Division of Clinical Science, St George's, University of London, London,Anthony D'Urzo2Department of Medicine, University of Toronto, Toronto, CanadaStephen Rennard3Department of Medicine, University of Nebraska Medical Center, Omaha,Eduard Molins4R&D Centre, Almirall S.A., Barcelona, SpainVictor Mergel5Forest Research Institute, Jersey City,Cynthia Caracta5Forest Research Institute, Jersey City,Anne Leselbaum4R&D Centre, Almirall S.A., Barcelona, Spain
- One-year efficacy of aclidinium/formoterol fixed-dose combination in COPD patients: The AUGMENT COPD studyBy Anthony D'Urzo, Stephen Rennard, Edward Kerwin, Victor Mergel, Thomas He, Anne Leselbaum and Cynthia CaractaAnthony D'Urzo1Department of Family and Community Medicine, University of Toronto, Toronto, CanadaStephen Rennard2Department of Internal Medicine, University of Nebraska Medical Center, Omaha,Edward Kerwin3Clinical Research Institute, Medford,Victor Mergel4Forest Research Institute, Jersey City,Thomas He4Forest Research Institute, Jersey City,Anne Leselbaum5R&D Centre, Almirall S.A., Barcelona, SpainCynthia Caracta4Forest Research Institute, Jersey City,
- Once-daily QVA149 improves dyspnoea, lung function and reduces rescue medication use in symptomatic patients with COPD using LAMA as prior medication: The BLAZE studyBy Anthony D'Urzo, Donald A. Mahler, Petter Olsson, Hungta Chen, Robert Fogel and Donald BanerjiAnthony D'Urzo1Department of Family and Community Medicine, University of Toronto, Toronto, ON, CanadaDonald A. Mahler2Section of Pulmonary & Critical Care Medicine, Geisel School of Medicine, Dartmouth, NH,Petter Olsson3Primary Care, Novartis Pharma AG, Basel, SwitzerlandHungta Chen4Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ,Robert Fogel4Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ,Donald Banerji4Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ,
- Glycopyrronium (GLY) and tiotropium (TIO) comparison: Lung function, dyspnea and health status in COPD patients in all GOLD groupsBy Anthony D'Urzo, Giovanni Bader, Pablo Altman and Pankaj GoyalAnthony D'Urzo1Department of Family and Community Medicine, Faculty of Medicine, University of Toronto, Toronto, CanadaGiovanni Bader2Novartis Pharma AG, Fabrikstrasse 2, Basel, SwitzerlandPablo Altman3Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesPankaj Goyal2Novartis Pharma AG, Fabrikstrasse 2, Basel, Switzerland
- Glycopyrronium significantly improves lung function, dyspnea and health status in COPD patients in all GOLD groupsBy Anthony D'Urzo, Giovanni Bader, Pablo Altman and Pankaj GoyalAnthony D'Urzo1Department of Family and Community Medicine, Faculty of Medicine, University of Toronto, Toronto, CanadaGiovanni Bader2Novartis Pharma AG, Fabrikstrasse 2, Basel, SwitzerlandPablo Altman3Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesPankaj Goyal2Novartis Pharma AG, Fabrikstrasse 2, Basel, Switzerland
Buying books on this site
Purchases made on this website are of electronic books only.
About the ERS books
The ERS Monograph is the quarterly book series from the European Respiratory Society. Each Monograph covers a specific area of respiratory medicine, providing in-depth reviews that give clinicians at all levels a concise, comprehensive guide to symptoms, diagnosis and treatment.
The ERS Handbooks are compact guides to broad areas of the respiratory field. Launched in 2010, the series now covers adult, paediatric and sleep respiratory medicine, includes a companion volume of self-assessment questions and features the ERS Practical Handbooks.
